Table 5. Prevalence and levels of autoantibodies in cerebrospinal fluid of patients with central and peripheral NPSLE at baseline and 6 monthsA .
| Autoantibodies positive, no. (%) | Central NPSLE Baseline (n = 25) | Central NPSLE 6 months (n = 25) | P (%) | Peripheral NPSLE Baseline (n = 5) | Peripheral NPSLE 6 months ( n = 5) | P (%) |
| Antinuclear | 15 (60) | 11 (44) | 0.26 | 5 (100) | 4 (80) | 1.0 |
| Anti-ds DNA | 17 (68) | 14 (53) | 0.61 | 3 (60) | 2 (40) | 1.0 |
| Anti-ribosomal | 10 (40) | 9 (36) | 0.95 | 2 (40) | 2 (40) | 1.0 |
| Anti-cardiolipin (IgG) | 4 (16) | 0 (0) | 0.11 | 0 (0) | 0 (0) | – |
| Anti-B2-Glycoprotein I (IgG) | 0 (0) | 0 (0) | – | 0 (0) | 0 (0) | – |
| Anti-N-Methyl-D-Aspartate Receptor (NMDAR) | 9 (39) | 5 (22) | 0.34 | 0 (0) | 2 (40) | 0.44 |
| Autoantibodies levels B | ||||||
| Anti-ds DNA | 463.3±1815.1 | 17.2±17.3 | 0.03 | 237.4±390.1 | 10.8±3.7 | 0.10 |
| Anti-ribosomal | 851.4±2061.6 | 25.1±21.6 | 0.01 | 30.9±14.4 | 12.5±3.1 | 0.17 |
| Anti-cardiolipin (IgG) | 10.7±2.7 | 4.0±0.5 | 0.06 | – | – | – |
| Anti-N-Methyl-D-Aspartate Receptor (NMDAR) | 82.9±39.9 | 76.3±93.1 | 0.26 | – | – | – |
A
The baseline evaluation was at the time of hospitalization. The NMDAR antibody was measured in 23 central and 5 peripheral NPSLE patients at baseline and 6 months.
B
Only patients who scored positive at baseline for the specific antibody were considered: Central NPSLE/Peripheral NPSLE anti-dsDNA 17/3, anti-ribosomal P 10/2, anticardiolipin IgG 4/0, anti-NMDAR 9/0.